Wilms tumor is one of the most prevalent pediatric malignancies in childhood cancer worldwide. A genome-wide association study recognized that LIM domain only 1 (LMO1) increases the risk of oncogenic potential. An association has been found that LMO1 gene polymorphisms are associated with the susceptibility to Wilms tumor. One hundred forty-five children with Wilms tumor and 531 cancer-free children were included in this hospital-based case-control study. Five potentially functional polymorphisms in the LMO1 gene (rs2168101 G>T, rs1042359 A>G, rs11041838 G>C, rs2071458 C>A and rs3750952 G>C) were genotyped by the TaqMan method. The association between selected polymorphisms and Wilms tumor susceptibility was measured by calculating the odds ratio (OR) and the 95% confidence interval (CI). Only rs2168101 G>T polymorphism was found to have a significant protective effect against Wilms tumor (GT vs. GG: adjusted OR=0.58, 95% CI=0.39-0.88, P=0.010; GT/TT vs. GG: adjusted OR=0.67, 95% CI=0. 46-0.97, P=0.034). Moreover, carriers of 3-5 protective genotypes had significantly lower tumor risk than carriers of 0-2 protective genotypes (adjusted OR=0.62, 95% CI=0.42-0.91, P=0.022). The stratified analysis showed that the protective effect of rs2168101 GT/TT was predominant in males, and rs2071458 GT/TT was predominant in females. Regarding the combined risk genotypes, the analysis indicated that the 3-5 protective genotypes collectively decreased Wilms tumor risk in females. These results suggest that LMO1 gene rs2168101 G>T polymorphism may help prevent Wilms tumor, but this conclusion should be verified in other populations and additional studies.
Introduction
Wilms tumor, which is the common name for nephroblastoma, has been recognized as one of the most prevalent pediatric malignancies in childhood cancer, generally developing in children under 5 years of age and morphologically resembling embryonic kidney [1] [2] [3] . It constitutes approximately 8% of all cancers among children younger than 15 years in Western populations [4] . In Western populations, the occurrence rate of Wilms tumor is approximately 1/8,000 children [5] , while the rate is approximately 3.3 cases per million in China [6] . Approximately 2% of Wilms tumor patients have a family history, and they are generally diagnosed as known causal genetic damage [7, 8] . However, no more than 5% of cases can be attributed to known causes, and the genetic basis underlying most Wilms tumor is not well understood [9] . Therefore, for Wilms tumor prevention and early diagnosis, it is important to identify risk factors and
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Genome-wide association study (GWAS) is a useful method employed without a hypothesis to find associations between susceptible genes and complex diseases, including tumors [9] . Previous GWASs and case-control studies have discovered several inherited susceptibility genes, such as FWT1 [10] , FWT2 [11] , BRCA2 [12] , TP53 [13, 14] , BARD1 [15] , CTR9 [16] , hOGG1 and FEN1 [17] , and XPD [18] that are significantly associated with the risk of Wilms tumor. To date , no polymorphisms within lncRNAs and Wilms tumor risk have been reported, despite their implication in carcinogenesis as either protooncogenes or an anti-oncogenes [19] . Recently, we validated a critical susceptibility gene LIM domain only 1 (LMO1) [20] in a hospital-based, case-control study with a total of 145 Wilms tumor children and 531 cancer-free children, one of the members of the LMO gene super-family. The cysteine-rich transcriptional regulator is encoded by 11p15 in the LMO1 gene, comprising two LIM zinc-binding domains. The LMO1 gene is mainly concentrated in the nervous system and participates in the development of the nervous system [21] . Overexpression of LMO1 was initially found in patients with T-cell acute lymphoblastic leukemia [22] .
In our previous study, four GWAS-identified LMO1 gene polymorphisms (rs110419 A>G, rs4758051 G>A, rs10840002 A>G and rs204938 A>G) were found to be associated with Wilms tumor susceptibility, but only the rs110419 A>G polymorphism may reduce the susceptibility to Wilms tumor [20] . Thus, other LMO1 gene polymorphisms require further determination to investigate Wilms tumor susceptibility. With this in mind, we carried out the current hospital-based case-control study with the same 145 Wilms tumor-bearing children and 531 cancer-free children to explore the association between five potentially functional polymorphisms in the LMO1 gene [rs2168101 G>T (a super-enhancer polymorphism identified by Oldridge et al.) [23] , rs1042359 A>G, rs11041838 G>C, rs2071458 C>A and rs3750952 G>C] and Wilms tumor susceptibility in a southern Chinese population.
Materials and methods

Study subjects
Detailed information on the recruitment criteria has been reported previously [15, [24] [25] [26] . From March 2001 to June 2016, we recruited 145 Wilms tumor patients from the Department of Pediatric Urology of the Guangzhou Women and Children Medical Center. Moreover, 531 cancer-free children from the same hospital who had undergone routine physical examinations were randomly selected as controls [27] [28] [29] [30] . All subjects were non-individual Han genetic individuals in South China. The response rate was approximately 90% for Wilms tumor patients and 95% for cancer-free controls. The Institutional Review Board of Guangzhou Women and Children's Medical Center approved this study, and each participant's parent or legal guardian provided medical informed consent.
Polymorphism analysis
Approximately 2 mL of peripheral blood was collected from each subject for DNA extraction. Five LMO1 potentially functional gene polymorphisms (rs2168101 G>T, rs1042359 A>G, rs11041838 G>C, rs2071458 C>A and rs3750952 G>C) were chosen for genotyping [31] . Genomic DNA was isolated from peripheral blood leukocytes through a TIANamp Blood DNA Kit (TianGen Biotech, Beijing, China). A 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) and TaqMan real-time PCR were used in the LMO1 gene polymorphism genotyping, as described in previous articles [32] [33] [34] [35] .
To acquire reliable results, we performed the genotyping blindly without knowledge of whether the subject was a case or control subject. Moreover, 10% of the samples were selected randomly for repeated assays, and the genotype concordance was 100%.
Statistical analysis
The χ 2 test was used to compare differences in the frequency distributions of demographic characteristics between cases and controls. The Hardy-Weinberg equilibrium for the genotype frequencies in controls was detected with a goodness-of-fit χ 2 test. To further explore the associations between LMO1 polymorphisms and Wilms tumor susceptibility, we calculated the odds ratio (OR) and the 95% confidence interval (CI) using non-conditional logistic regression and adjusting for age and gender. All tests were two-sided. P<0.05 was considered statistically significant. All statistical analyses were performed with SAS software (Version 9.4; SAS Institute, Cary, NC).
Results
Population characteristics
Overall, 145 patients with Wilms tumor and 531 cancer-free children were included in our analysis. The demographic characteristics of the Wilms tumor children and the cancer-free children are presented in Supplementary GT/TT, rs1042359 AG/AA, rs11041838 GC/GG, rs2071458 CA/AA and rs3750952 GC/CC genotypes.
Stratification analysis
We performed an analysis stratified by age, gender, and clinical stages to further evaluate the combined effect of LMO1 gene polymorphisms (rs2168101 G>T and rs2071458 C>A) and the susceptibility of Wilms tumors given protective genotypes ( Table 2 ). Compared to the rs2168101 GG genotype, the protective effect of the GT/TT genotype was more predominant in males (adjusted OR=0.50, 95% CI=0.30-0.84, P=0.009). Nevertheless, the rs2071458 CA/AA genotype was more predominant in females (adjusted OR=0.36, 95% CI=0.19-0.70, P=0.003). In addition, the combined analysis indicated that the 3-5 protective genotypes obviously decreased Wilms tumor susceptibility in females (adjusted OR=0.55, 95% CI=0.30-0.99, P=0.045).
Genotype-based mRNA expression analysis
As shown in Figure 1 , the rs2168101 G>T polymorphism was also associated with altered LMO1 mRNA expression in skeletal muscle tissues based on the public database GTEx Portal (http://www.gtex portal.org/home/) [18, 37] .
Discussion
In the current hospital-based case-control study, we explored the association of five LMO1 gene polymorphisms with Wilms tumor susceptibility in 145 patients and 531 cancer-free controls. Although an association between LMO1 gene polymorphisms and Wilms tumor susceptibility in Chinese children has been reported by our team, there are many more LMO1 gene polymorphisms worthy of exploration. In this study, we verified that the super-enhancer rs2168101 G>T polymorphism was significantly associated with a decreased risk of Wilms tumor, which was similar to the trend for neuroblastoma [23, 31] .
On the basis of GWAS research, there is growing evidence that LMO1 is a significant determinant of cancer susceptibility. Wang et al. identified that four genetic variants of LMO1 (rs110419 A>G, rs4758051 G>A, rs10840002 A>G and rs204938 A>G) contributed to tumorigenesis ability in neuroblastoma among individuals of European descent [38] . Subsequently, this LMO1 gene polymorphism susceptibility was further confirmed in five other epidemiological studies of different ethnicities [39] [40] [41] [42] [43] . Apart from neuroblastoma, LMO1 gene polymorphisms were also associated with acute lymphoblastic leukemia susceptibility. In Caucasian children (163 patients and 251 controls), Beuten et al. found an association between another genotype of the LMO1 gene (rs442264 A>G) and susceptibility to acute lymphocytic leukemia [44] . In addition, recent studies have indicated that in anti-EGFR therapy, overexpression of LMO1 may be a predictive marker for colorectal cancer [45] , lung cancer [46] and prostate cancer [47] . The associations of the LMO1 gene polymorphisms (rs110419 A>G, rs4758051 G>A, rs10840002 A>G and rs204938 A>G) with Wilms tumor susceptibility were reported in our previous study. Here, we performed a further study on the associations between five LMO1 gene polymorphisms (rs2168101 G>T, rs1042359 A>G, rs11041838 G>C, rs2071458 C>A and rs3750952 G>C) and Wilms tumor susceptibility in 145 patients and 531 healthy controls. We found that the GT/TT genotypes of the rs2168101 G>T polymorphism correspond to a significant decrease in Wilms tumor susceptibility, while we failed to detect significant associations between the other four polymorphisms and Wilms tumor susceptibility. The rs2168101 GT/TT genotypes carriers had a significantly decreased Wilms tumor risk. The protective effects of this SNP may be ascribed to the lower expression of LMO1 gene which is confirmed by Oldridge et al. [23] as well as data from GTEx database. Among these five polymorphisms we observed, the rs2168101 G>T polymorphism corresponded to a significant decrease in Wilms tumor susceptibility only for the rs2168101 GT carriers compared with the GG carriers, suggesting a protective effect of this polymorphism against Wilms tumor. There did not seem to be an association between the other four polymorphisms and Wilms tumor susceptibility. The relatively small sample size of this current study might have limited the statistical power for detecting a difference. Non-significant SNPs in the single locus analysis may collectively modify Wilms tumor susceptibility. Not surprisingly, the combined analysis indicated that 3-5 protective genotypes obviously decreased Wilms tumor susceptibility in females. However, there is still no direct evidence showing the exact association of LMO1 gene polymorphisms (rs2168101 G>T and rs2071458 C>A) with gender and clinical stage.
Several potential limitations of the current study may be ascribed to the following: 1) the relatively small sample size and lacking of multi-center clinical study, 2) the consideration of only five polymorphisms that lack potential function, and 3) the influence of environmental factors on Wilms tumor susceptibility.
In conclusion, we verified that the LMO1 super-enhancer rs2168101 G>T polymorphism was also significantly associated with a decreased risk of Wilms tumor.
